Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
12
01
2023
accepted:
04
09
2023
revised:
22
08
2023
pubmed:
20
9
2023
medline:
20
9
2023
entrez:
19
9
2023
Statut:
ppublish
Résumé
Germ cell tumors (GCT) might undergo transformation into a somatic-type malignancy (STM), resulting in a cell fate switch to tumors usually found in somatic tissues, such as rhabdomyosarcomas or adenocarcinomas. STM is associated with a poor prognosis, but the molecular and epigenetic mechanisms triggering STM are still enigmatic, the tissue-of-origin is under debate and biomarkers are lacking. To address these questions, we characterized a unique cohort of STM tissues on mutational, epigenetic and protein level using modern and high-throughput methods like TSO assays, 850k DNA methylation arrays and mass spectrometry. For the first time, we show that based on DNA methylation and proteome data carcinoma-related STM more closely resemble yolk-sac tumors, while sarcoma-related STM resemble teratoma. STM harbor mutations in FGF signaling factors (FGF6/23, FGFR1/4) highlighting the corresponding pathway as a therapeutic target. Furthermore, STM utilize signaling pathways, like AKT, FGF, MAPK, and WNT to mediate molecular functions coping with oxidative stress, toxin transport, DNA helicase activity, apoptosis and the cell cycle. Collectively, these data might explain the high therapy resistance of STM. Finally, we identified putative novel biomarkers secreted by STM, like EFEMP1, MIF, and DNA methylation at specific CpG dinucleotides.
Sections du résumé
BACKGROUND
BACKGROUND
Germ cell tumors (GCT) might undergo transformation into a somatic-type malignancy (STM), resulting in a cell fate switch to tumors usually found in somatic tissues, such as rhabdomyosarcomas or adenocarcinomas. STM is associated with a poor prognosis, but the molecular and epigenetic mechanisms triggering STM are still enigmatic, the tissue-of-origin is under debate and biomarkers are lacking.
METHODS
METHODS
To address these questions, we characterized a unique cohort of STM tissues on mutational, epigenetic and protein level using modern and high-throughput methods like TSO assays, 850k DNA methylation arrays and mass spectrometry.
RESULTS AND CONCLUSIONS
CONCLUSIONS
For the first time, we show that based on DNA methylation and proteome data carcinoma-related STM more closely resemble yolk-sac tumors, while sarcoma-related STM resemble teratoma. STM harbor mutations in FGF signaling factors (FGF6/23, FGFR1/4) highlighting the corresponding pathway as a therapeutic target. Furthermore, STM utilize signaling pathways, like AKT, FGF, MAPK, and WNT to mediate molecular functions coping with oxidative stress, toxin transport, DNA helicase activity, apoptosis and the cell cycle. Collectively, these data might explain the high therapy resistance of STM. Finally, we identified putative novel biomarkers secreted by STM, like EFEMP1, MIF, and DNA methylation at specific CpG dinucleotides.
Identifiants
pubmed: 37726478
doi: 10.1038/s41416-023-02425-5
pii: 10.1038/s41416-023-02425-5
pmc: PMC10645790
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1580-1589Subventions
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : NE 1861/8-1
Organisme : Wilhelm Sander-Stiftung (Wilhelm Sander Foundation)
ID : 2016.042.1 /.2 /.3
Informations de copyright
© 2023. The Author(s).
Références
Nat Rev Cancer. 2005 Mar;5(3):210-22
pubmed: 15738984
J Urol. 1994 Oct;152(4):1144-9
pubmed: 8072083
Cancer. 1985 Aug 15;56(4):860-3
pubmed: 2990657
Histopathology. 2021 Mar;78(4):593-606
pubmed: 32970854
Biol Chem. 2009 Dec;390(12):1293-302
pubmed: 19804359
Semin Diagn Pathol. 1987 Nov;4(4):304-19
pubmed: 2832917
Am J Surg Pathol. 2014 Oct;38(10):1396-409
pubmed: 24921638
Arch Pathol Lab Med. 1989 Oct;113(10):1115-9
pubmed: 2478105
Am J Surg Pathol. 2022 Jan 1;46(1):11-17
pubmed: 34334690
Asian J Urol. 2021 Apr;8(2):144-154
pubmed: 33996469
J Histochem Cytochem. 1998 Mar;46(3):397-403
pubmed: 9487122
Genome Biol. 2003;4(5):P3
pubmed: 12734009
Virchows Arch. 2012 Jul;461(1):27-32
pubmed: 22622519
J Urol. 2014 Nov;192(5):1403-9
pubmed: 24952240
Cancer. 1984 Nov 1;54(9):1824-33
pubmed: 6090001
Urol Oncol. 2008 Nov-Dec;26(6):595-9
pubmed: 18367105
Int J Surg Pathol. 2011 Jun;19(3):321-7
pubmed: 21134986
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Eur Urol. 2022 Nov;82(5):458-468
pubmed: 35853783
Mod Pathol. 2022 Dec;35(12):1966-1973
pubmed: 36030288
Nat Rev Dis Primers. 2018 Oct 5;4(1):29
pubmed: 30291251
Nat Protoc. 2019 Jan;14(1):68-85
pubmed: 30464214